BMO Capital Markets Hosts 2026 Metabolic Health Summit on Advancements in GLP-1 Therapies

BMO Capital Markets Hosts 2026 Metabolic Health Summit: Pioneering Innovations in Metabolic Science

BMO Capital Markets is set to host the 2026 Metabolic Health Summit on March 24, 2026, in New York City, representing a significant evolution from its previous Obesity Summit. The conference aims to assemble key industry leaders, innovators from the BioPharma sector, and investors to delve into advancements in metabolic health, with a particular focus on GLP-1 therapies. These therapies are gaining recognition for their transformative impact on conditions including obesity, diabetes, heart failure, and renal health. Scheduled to take place at the Westin Grand Central from 7:30 a.m. to 4:30 p.m. ET, the summit will feature a range of engaging activities designed to foster dialogue about the future of healthcare in this area.

The summit's agenda includes various thought leadership panels, fireside chats, and one-on-one meetings that spotlight the most pressing issues in metabolic health. Notable speakers include industry veterans such as Dr. Katherine Saunders, who will present "Obesity 103," and Dr. Louis J. Aronne, who will discuss the state of Obesity Medicine in 2026. The inclusion of leading companies such as Eli Lilly, Amgen, and Pfizer underscores the collaborative effort to address the rising tide of metabolic diseases. The event aims to bridge gaps between pharmaceutical advancements and healthcare delivery, examining patient insights on GLP-1+ therapy alongside contributions from care delivery organizations like WeightWatchers and Ro Health.

BMO Financial Group, recognized as the eighth largest bank in North America, emphasizes its commitment to healthcare innovation by facilitating this pivotal summit. By providing a platform for insightful discussions and exchanging knowledge, BMO Capital Markets seeks to play an influential role in shaping the future of metabolic health solutions. The gathering promises to foster collaboration and advance understanding among healthcare stakeholders, further underscoring the importance of addressing metabolic diseases in contemporary medical research and practice.

In addition to the rich agenda, the summit offers an opportunity for meaningful networking among participants. By bringing together stakeholders from diverse segments of the healthcare industry, BMO reinforces its position as a leader in financial services while contributing to the discourse surrounding crucial health issues. As attendees engage in discussions on cutting-edge therapies and emerging technologies, the summit sets the stage for significant advancements in the management of metabolic health. For further details about the summit’s agenda and participating organizations, interested parties can connect with BMO Media Relations.